RedShiftBio Expands Team to Support Launch of FlagShip AQS³®pro System for Protein Characterization

Burlington, MA 14 March 2018. Following the introduction of the AQS³®pro, a new protein characterization platform that allows users to ‘See Change™, in the secondary structure of proteins, RedShiftBio has announced that it is expanding its team with key hires. The growth will enable the company to fulfil high demand for the new instrument.

John Linnan, a sales and marketing executive with a strong background in the life sciences, joins the company as North American sales manager. John’s career has spanned start-ups to industry leaders. As Global VP of Sales and Marketing, he helped transition Agencourt BioScience into a wholly-owned subsidiary of Beckman Coulter. He also developed and executed the commercialization strategy for QIAGEN Custom Solutions (formally Enzymatics) for enzyme manufacturing and OEM solutions targeting biotech drug & diagnostics development. This experience makes John the perfect appointment to help build our commercial channels for our new technology platform. The AQS³pro is designed for the development, formulation and manufacture of biotherapeutics. Enabling five key measurements—aggregation, quantitation, stability, similarity, structure—the AQS³pro ramps up the sensitivity, dynamic range and accuracy of IR spectroscopy over the concentration range of 0.1 to 200mg/mL. It features a powerful, integrated bioanalytics software that delivers automated, high sensitivity spectroscopic analysis.

If you would like to find out more about the AQS³pro then visit https://redshiftbio.com/mms.